

**EBD MEDICAL DRUG
RECOMMENDATIONS
(Aug 2025)**

August 2025 Medical Drug Recommendations to EBD Commission

Drug	Treating Diagnosis	EBD Recommendation from EBRx	Comment	Cost (AWP unless otherwise mentioned)	Change	Impacted Members	EBD Commissions	Board of Finance
Bkemv (eculizumab-AEEB)	Atypical hemolytic uremic syndrome (aHUS), Paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD)	Exclude	Biosimilar of Soliris, interchangeable	\$7,045/300mg vial, \$732,680 per year	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Epysqli (eculizumab-AAGH)		Cover with PA	Biosimilar of Soliris. Lowest cost eculizumab based on AWP.	\$5,480/300mg vial \$569,920 per year	NTM to Cover with PA	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Jubbonti (denosumab 60mg/mL)	Osteoporosis/bone loss	Cover with PA	Biosimilar of Prolia, Interchangeable	\$3,849.92 per year (1 injection every 6 months)	NTM to Cover with PA	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Stoboclo (denosumab 60mg/mL)		Exclude	Biosimilar of Prolia	\$4,275.98 per year (1 injection every 6 months)	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Prolia (denosumab 60mg/mL)		Exclude	Original biologic	\$4,501.04 per year (1 injection every 6 months)	Cover with PA to Exclude	126 (90 day grandfather)	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Wyost (denosumab 120mg/1.7mL)	Bone metastases from solid tumors, Giant cell tumor of bone, hypercalcemia of malignancy, multiple myeloma	Cover with PA	Biosimilar of Xgeva, Interchangeable	\$46,188 per year assuming 1 injection every 4 weeks	NTM to Cover with PA	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Osenvelt (denosumab 120mg/1.7mL)		Exclude	Biosimilar of Xgeva	\$47,192.40 per year assuming 1 injection every 4 weeks	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Xgeva (denosumab 120/1.7mL)		Exclude	Original Biologic	\$49,676.28 per year assuming one injection every 4 weeks	Cover with PA to Exclude	50 (90 day grandfather)	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Imuldosa (ustekinumab-SRLF)	Crohn disease, ulcerative colitis, Hidradenitis Suppurativa, plaque psoriasis, psoriatic arthritis	Exclude	Biosimilar of Stelara	\$2,798.54 per 90mL injection, \$18,187 per year if given every 8 weeks	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Pyzchiva (Ustekinumab-TTWE)		Exclude	Biosimilar of Stelara	\$4,980.00 per 90mL injection, \$32,370 per year if given every 8 weeks	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Aucatzyil (obecabtagene autoleucel or obe-cel)	Acute Lymphoblastic Leukemia	Exclude	CAR-T, Brexu-cel has better OS but higher rate of temporary SE compared to Obe-cel, durable results	\$630,000 once, does not include admin or hospital costs	No EBRx Restrictions To Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Carvykti (ciltacabtagene autoleucel or cilta-cel)	Multiple Myeloma	Cover with no EBRx Restrictions Cover with PA	CAR-T, Meta-analysis shows cilta-cel to be superior over ide-cel	\$555,310 (WAC) once, does not include admin or hospital costs	No EBRx Restrictions to PA	0	<i>Approve Recommendation as amended</i>	<i>Approve Recommendation from the EBD Commissions</i>
Abecma (idecabtagene vicleucel or ide-cel)	Multiple Myeloma	Exclude	CAR-T, Meta-analysis shows cilta-cel to be superior over ide-cel	\$528,213 (WAC) once, does not include admin or hospital costs	No EBRx Restrictions To Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Vimkunya (chikungunya vaccine)	Prevention of Chikungunya virus disease	Exclude	Travel vaccine, Mosquito borne disease, mostly in South America, Africa and India, recomb vaccine	\$330 once	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Ebanga (ansuvimab-ZYKL)	Prevention of ebola virus	Cover with no EBRx restrictions	National stockpile	no cost	NTM to No EBRx Restrictions	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>

Drug	Treating Diagnosis	EBD Recommendation from EBRx	Comment	Cost (AWP unless otherwise mentioned)	Change	Impacted Members	EBD Commissions	Board of Finance
Qfitlia (fitusiran)	Hemophilia A or B, prophylaxis	Exclude	Does improve bleeding risk and QOL, but waiting for cost effectiveness evaluation	Up to \$2.3M per year based on bleeding response	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Besremi (ropeginterferon alfa)	Polycythemia vera	Cover with PA	Updated long-term data added Besremi to the NCCN recommendations	Up to \$264,672 per year (dose based on hematologic lab work)	Exclude to cover with PA	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Zevtera (ceftobiprole medocartil IV)	Bacteremia, CAP, SSTI	Cover with No EBRx Restrictions	Included in the DRG (inpatient costs)	\$4,230 - \$13,536 per course based on diagnosis	NTM to No EBRx restrictions	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Ryzneuta (efbarmalenograstim alfa-VUXW)	To decrease incidence of infection from febrile neutropenia	Exclude	Long acting agent comparable to low cost pegfilgrastin (Fulphila)	\$22,080 per cycle (every 3 weeks)	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Emblaveo (aztreonam/avibactam vial)	Complicated intra-abdominal bacterial infection	No EBRx restrictions	New Combo of already available antibiotics, given in-patient and will fall under the DRG	\$7,840 per course	NTM to No EBRx Restrictions	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Zevaskyn (prademagene zamikeracel gene therapy sheets)	Dystrophic epidermolysis bullosa treatment	Exclude	Need cost effectiveness, unknown durability and the need for reapplications, Plan does not currently cover Gene therapy	\$3.7M per sheet, may use up to 12 sheets per application	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Ablysinol (ethyl alcohol 99%)	To induce controlled cardiac septal infarction during cardiac surgery	No EBRx restrictions	Line extension with new strength, to be used with cardiac surgery and will fall under the DRG	\$995 per procedure	NTM to No EBRx Restrictions	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Enflonsia (clesrovimab-CFOR)	Prevention of RSV in infants	No EBRx restrictions	25% absolute reduction in RSV-associated medically attended lower respiratory infections and hospitalizations	\$556 per injection for 1-2 doses	NTM to No EBRx Restrictions	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Ryoncil (remestemcel)	Steroid-refractory acute graft-versus-host disease	Exclude	Infusion of mesenchymal stromal cells	\$1.9M in the first month, repeat if necessary	NTM to Exclude	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Erzofri (paliperidone)	Schizophrenia	No EBRx Restrictions	Comparable once monthly dosing and cost as Invega Sustenna (No EBRx restrictions)	Up to \$3,116.91 per month injection	No change	0	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>
Syfovre (pegcetacoplan intravitreal inj)	Geographic atrophy	Exclude	Lack of functional benefit to any subgroup of patients in the trial, associated risks of serious vasculitis and vision loss	\$79,628 per year (for both eyes)	No EBRx Restrictions To Exclude	4 (90 day grandfather)	<i>Approve Recommendation</i>	<i>Approve Recommendation</i>

NTM = new to market, No EBRx Restrictions = coverage will fall under health advantage policy

PA will be managed by EBRx, If no change occurs then the drug was re-reviewed by EBRx clinical committee for new data but no change in coverage